Cancer Immunology |
Autore | Subramanian Subree |
Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 |
Descrizione fisica | 1 electronic resource (316 p.) |
Soggetto topico | Medicine |
Soggetto non controllato |
NKG2D
CAR T IL-7 prostate cancer cell therapy CD19-CAR-T B cell aplasia KIR PD-1 inhibitory CAR tumor-infiltrating lymphocytes tumor microenvironment immunotherapy NK cells cancer stem cells (CSCs) antibody-dependent cellular cytotoxicity (ADCC) differentiation cytotoxicity IFN-γ osteoclasts MICA/B mAb DNA methylation RNA methylation S-adenosylmethionine (SAM) cancer innate immunity adaptive immunity T cells m6A PD-L1 resistance immune checkpoints cancer vaccine combination immunotherapy TCR diversity organ transplantation carcinoma epidemiologic studies immunosuppression CTLA-4 Treg cells immune checkpoint inhibitors CD28 antigen-presenting cells IL15 colon cancer melanoma uveal BAP1 anti-PD-1 anti-CTLA-4 TIL classical and endemic Kaposi Sarcoma systemic treatment multi-state modelling treatment free interval chemotherapy interferon triple negative breast cancer immunomodulation bispecific antibody sortase A chemo-enzymatic approach anti-CD20 antibody Fab BiFab colorectal cancer dendritic cells Atypical Chemokine Receptor 4 (ACKR4) T-cell priming immune checkpoint blockade primary liver cancer kynurenine pathway immune evasion indoleamine 2,3 dioxygenase 1 tryptophan 2,3 dioxygenase 2 IDO inhibitor antigen presenting cells |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910557349203321 |
Subramanian Subree
![]() |
||
Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Innovations in the Integrated Management of Breast Cancer |
Autore | Franceschini Gianluca |
Pubbl/distr/stampa | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
Descrizione fisica | 1 electronic resource (278 p.) |
Soggetto topico |
Medicine
Pharmacology |
Soggetto non controllato |
metastatic breast cancer
breast surgery immune system metabolic derangements precision medicine integrated therapies advanced breast cancer mTOR inhibitor CDK4/6 inhibitor endocrine resistance breast cancer pregnancy chemotherapy tailoring personalization DataMart real world data predictive model healthcare breast-conserving surgery non-palpable breast lesions image-guided localization preoperative breast localization breast ultrasound large database standardized data collection networks nipple-sparing mastectomy immediate breast reconstruction acellular dermal matrix (ADM) aesthetic and oncological outcomes quality of life rare breast cancer osteoclast-like giant cells gene profiling Oncotype Dx adjuvant treatment neoadjuvant chemotherapy sentinel lymph node systemic treatment locally advanced breast cancer mini-invasive treatment liver metastases hepatic surgery personalized medicine sarcopenia physical performance frailty older cancer patients clinical trial patient enrollment artificial intelligence machine learning lung cancer oncology web app conventional CT and CT angiography DIEP flap planning multidisciplinary treatment evidence-based medicine personalized treatment oncological outcomes patient quality of life normal breast breast pathology hormone receptor hormone expression lymphedema lymphaticovenous anastomosis vascularized lymph node transfer lymphatic microsurgery radiotherapy oligometastatic breast cancer locoregional therapy CDK4/6 inhibitors multidisciplinary AMH ovarian reserve pregnancy desire subtypes breast cancer miRNAs breast cancer treatment next-generation-sequencing target therapy old age survival vitamin D ductal breast cancer in situ breast cancer lobular breast cancer histology |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910566478003321 |
Franceschini Gianluca
![]() |
||
Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
New Therapies of Liver Diseases |
Autore | Toniutto Pierluigi |
Pubbl/distr/stampa | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
Descrizione fisica | 1 electronic resource (236 p.) |
Soggetto topico | Public health & preventive medicine |
Soggetto non controllato |
tolvaptan
cirrhotic ascites survival rate furosemide primary biliary cholangitis autoantibodies ursodeoxycholic acid treatment response second line therapy primary biliary cholangitis (PBC) primary sclerosing cholangitis (PSC) clinical trials ursodeoxycholic acid (UDCA) Farnesoid X Receptor (FXR) agonist Pan-Peroxisome Proliferator-Activated Receptor (PPAR) agonists liver cancer systemic treatment immunotherapy real-world unresectable hepatocellular carcinoma cirrhosis decompensation bleeding varices survival infection alcoholic hepatitis acute-on-chronic liver failure cholangiocarcinoma colorectal cancer metastases hepatocellular carcinoma liver transplantation Milan criteria alpha-fetoprotein solid organ transplantation liver injury immunosuppressant SARS-CoV-2 humoral response vaccination portal-systemic shunt ammonia vigilance HBV HDV antivirals functional cure pharmacology acute-on-chronic liver failure (ACLF) liver transplantation (LT) decompensated cirrhosis portal hypertension ascites non-selective beta-blockers TIPS rifaximin human albumin statins targeted therapy effective hypovolemia anti-mineralocorticoids loop diuretics vaptans |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910566457403321 |
Toniutto Pierluigi
![]() |
||
Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|